Aurobindo Pharma Ltd. (NSE: AUROPHARMA, BSE: 524804) is a Hyderabad, Telangana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹95,910 Cr, it ranks #119 by market cap among the 6,137 Indian listed companies on FinBizNet, and #6 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,571.70 (as of 25 Oct 2026), the share price is 9.7% below its 52-week high of ₹1,740.00 and 45.5% above its 52-week low of ₹1,080.10. The share price is up 41.7% over one year and up 2.6% over three months.
| Current Price | ₹1,571.70 |
|---|---|
| Market Cap | ₹95,910 Cr |
| NSE Symbol | AUROPHARMA |
| BSE Code | 524804 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 26.8 |
| Return on Equity | 9.93% |
| Return on Assets | 5.95% |
| 52-Week Range | ₹1,080.10 – ₹1,740.00 |
| 1-Year Price Change | +41.7% |
| 3-Month Price Change | +2.6% |
| Beta (1Y) | 0.11 |
| Dividend Yield | 0.00% |
| Headquarters | Hyderabad, Telangana |
| Website | www.aurobindo.com |
| Revenue | ₹9,150 Cr |
|---|---|
| Net Profit | ₹1,034 Cr |
| Net Margin | 11.3% |
| EPS (Basic) | ₹17.86 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin’s, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
1. Bulk Drugs-This segment engages in manufacturing and marketing active pharmaceutical ingredients, generic pharmaceuticals, and related services. 2. Formulations-This segment manufactures semi-synthetic penicillins, and value added products, such as cephalsoporins, quinolones, macrolides, and other bulk actives. 3. Other Operations-This segment manufactures finished dosages mainly in the categories of gastro respiratory infection pain; cardio neuro diabetes psychiatry; AIDS; and analgesics, anti infectives, and cough and cold injectables. 4. Research & Development-This segment engages in trading and investing activities.
1. Pharmaceutical Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Glenmark Pharmaceuticals Limited | ₹62,838 Cr | 45.7 | 14.07% | ₹4,018 Cr | +16.2% |
Listed by market capitalisation. Ratios are shown for context only.
Aurobindo Pharma Ltd. is trading at ₹1,571.70, with a market capitalisation of ₹95,910 Cr.
Aurobindo Pharma Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Aurobindo Pharma Ltd. has a P/E of 26.8 and a return on equity of 9.93%.
Aurobindo Pharma Ltd. is listed on the NSE under the symbol AUROPHARMA and on the BSE under the scrip code 524804.
Aurobindo Pharma Ltd.'s share price is up 41.7% over one year and up 2.6% over three months. Its 52-week range is ₹1,080.10 to ₹1,740.00.
In Q1 FY27, Aurobindo Pharma Ltd. reported revenue of ₹9,150 Cr and net profit of ₹1,034 Cr, with basic EPS of ₹17.86 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.